1. Medtech Insight
  2. >>Minute Insights

Minute Insight: FTC Pressure Kills Cooper’s Planned Deal For Cook’s Reproductive Assets

 
• By Reed Miller

Cooper announced a plan to buy Cook’s reproductive health business in February. The deal would have been worth $675m up front and $200m in four annual installments. The US FTC determined the deal would have impaired competition in the reproductive health market.

Minute Insight
• Source: Citeline/Alamy

The Cooper Companies (Cooper) are abandoning a planned $875m acquisition of Cook Medical’s reproductive health business after US antitrust regulators determined the deal would be anticompetitive.

In February 2022, Cook signed a letter of intent to sell its reproductive health business to Cooper for about $675m upon closing and $200m more in four $50m annual installments

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Minute Insights

Minute Insight: Haemonetics Buys OpSens To Add Fiber-Optic Sensors For Intervention

 
• By Reed Miller

Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.

Minute Insight: Best Buy Will Sell Dexcom CGM

 
• By Reed Miller

The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.

Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators

 
• By Barnaby Pickering

Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

 
• By Reed Miller

Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.

More from Medtech Insight

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.